Table 1 Demographic and clinical characteristics between schizophrenia patients and healthy controls
|  | HCs(n = 70) | SCZ(n = 70) | t/c2 | P value | 95% CI of the Difference | |
|---|---|---|---|---|---|---|
Lower | upper | |||||
Age | 35.80(9.90) | 35.54(10.35) | t=-0.12 | 0.905 | -3.00 | 3.00 |
Male gender, n (%) | 39(55.7%) | 39(55.7%) | c2 = 0 | 1.000 |  |  |
BMI | 23.58(3.63) | 24.69(4.06) | t=-2.01 | 0.044 | 0.03 | 2.61 |
Education (years) | 13.33(2.67) | 11.40(3.40) | t=-3.16 | 0.002 | -3.00 | 0.00 |
Smokers, n (%) | 26(37.1%) | 20(28.6%) | c2 = 1.17 | 0.280 | 0.48 | 1.24 |
Family history, n (%) | Â | 13(18.6%) | Â | Â | 0.09 | 0.28 |
Duration of illness (months) | 124.77(111.28) | Â | Â | 98.24 | 151.31 | |
PLT (10^9/L) | 2.36(0.07) | 2.41(0.12) | t=-2.781 | 0.006 | -0.08 | -0.01 |
Neutrophils (10^9/L) | 0.61(0.08) | 0.74(0.14) | t=-6.639 | < 0.0001 | -0.17 | -0.09 |
Lymphocytes (10^9/L) | 0.46(0.06) | 0.46(0.09) | t = 0.131 | 0.896 | -0.02 | 0.03 |
Monocytes (10^9/L) | 0.12(0.03) | 0.19(0.05) | t=-7.613 | < 0.0001 | -0.07 | -0.04 |
NLR | 0.42(0.07) | 0.54(0.15) | t=-6.028 | < 0.0001 | -0.16 | -0.08 |
PLR | 2.08(0.09) | 2.14(0.16) | t=-2.434 | 0.016 | -0.10 | -0.01 |
MLR | 0.07(0.02) | 0.11(0.04) | t=-7.264 | < 0.0001 | -0.05 | -0.03 |
Chlorpromazine equivalent doses | 506.29(242.31) | Â | Â | 448.51 | 564.06 | |
Antidepressants, n (%) | Â | 7(10.0%) | Â | Â | 0.03 | 0.17 |
Lithium, n (%) | Â | 2(2.9%) | Â | Â | -0.01 | 0.07 |
Propranolol, n (%) | Â | 5(7.1%) | Â | Â | 0.01 | 0.13 |
Benzodiazepines, n (%) | Â | 3(4.3%) | Â | Â | -0.01 | 0.09 |
Non-benzodiazepine hypnotics, n (%) | 14(20.0%) | Â | Â | 0.10 | 0.30 | |